42 reports

  • 6.1 INTRODUCTION
  • FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016-2023 (USD MILLION)

PREBIOTICS RESIST GASTRIC ACIDITY AND HYDROLYSIS CAUSED BY ENZYMES AND GASTROINTESTINAL ABSORPTION.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Market Size
  • Arla Foods
  • Cargill Inc.

One of the major reasons for the high bioavailability of organic minerals is that, unlike inorganic minerals, these do not interact with fiber, tannin, phytate, silicates, oxalate, or other minerals in the gastrointestinal tract.

  • Mineral Supplement
  • Pig
  • World
  • Alltech Inc.
  • Kemin Industries, Inc.

THE MICROPEARLS SPRAY FREEZING TECHNOLOGY ALLOWS FOR THE TIMELY RELEASE OF THESE ## KEY NUTRIENTS THROUGHOUT AN ANIMAL' S GASTROINTESTINAL TRACT.

  • Mineral Supplement
  • North America
  • United States
  • World
  • Market Size
  • VITAMIN & MINERAL PREMIXES MARKET, BY FUNCTIONALITY

Q. ##.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Market Size
  • Glanbia plc
  • Nutreco N.V.

MARKET ##.

  • Mineral Supplement
  • APAC
  • Japan
  • World
  • Demand

You can easily book an appointment with one online.

  • Mineral Supplement
  • World
  • Market Size
  • Alltech Inc.
  • Kemin Industries, Inc.
  • BILE ACID SEQUESTRANTS
  • LOSS OF PATENT EXCLUSIVITY OF BRANDED THERAPIES

The prevalence rate for FH ranges between one in ## to one in ## people.

  • Lipid Modifying Drug
  • Mineral Supplement
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 13.3 Factors that impede market growth

Bile acid sequestrates lead to side effects related to the gastrointestinal tract.

  • Cholesterol
  • Lipid Modifying Drug
  • Mineral Supplement
  • World
  • AstraZeneca PLC

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Mineral Supplement
  • China
  • Demand
  • Amway Corporation
  • Joincare Pharmaceutical Group Industry Co., Ltd.
  • WELCHOL SWOT ANALYSIS, 2015
  • 6.12 BILE ACID SEQUESTRANTS

PLOS ONE; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Energy
  • Mineral Supplement
  • Vitamin
  • China
  • Demand

It is estimated that worldwide one in five men and one in three women are at risk of an osteoporotic fracture.

  • Mineral Supplement
  • World
  • Forecast
  • Quidel Corporation
  • Roche Group

The subsidiary is focused on aging care, critical care & surgery, gastrointestinal function, and pediatrics.

  • Lipid Modifying Drug
  • Mineral Supplement
  • North America
  • United States
  • Demand

Q. ##.

  • Lipid Modifying Drug
  • Meat
  • Mineral Supplement
  • Cargill Inc.
  • Koninklijke DSM N.V.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It acts by targeting free fatty acid receptor ## (GPR##).

  • Diabetes
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • DYSLIPIDEMIA - PIPELINE BY JEIL PHARMACEUTICAL CO LTD, H1 2018

Dyslipidemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation...

  • Cholesterol
  • Chronic Disease
  • Lipid Modifying Drug
  • Mineral Supplement
  • Amarin Corporation plc

S##. and Rehabilitation; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

GlobalData Nutritional Disorders Genito Urinary System And Sex Hormones Hematological Disorders Hormonal Disorders ## ##. ## ## ##. ## ## ##. ## ## ##. ## Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD

  • Health Services
  • Lipid Modifying Drug
  • India
  • M&A
  • Lifesciences Limited

GlobalData Nutritional Disorders Genito Urinary System And Sex Hormones Hematological Disorders Hormonal Disorders ## ##. ## ## ##. ## ## ##. ## ## ##. ## Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD

  • Health Services
  • Lipid Modifying Drug
  • India
  • M&A
  • Lifesciences Limited
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Unspecified, Diabetes, Type ## Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD) and Non- Alcoholic Steatohepatitis (NASH).

  • Lipid Modifying Drug
  • Molecular Diagnostic
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • HYPERLIPIDEMIA - PIPELINE BY LOTUS PHARMACEUTICAL CO., LTD., H1 2016
  • HYPERLIPIDEMIA - PIPELINE BY ALLERGAN PLC, H1 2016

The company also focuses in the infection, neuroscience and gastrointestinal (ING) disease areas.

  • Endocrine Disease
  • Lipid Modifying Drug
  • Mineral Supplement
  • United States
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ##, ## and ## respectively.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Therapy
  • World
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

These one-year data extend and affirm the six-month results from ORION-##.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative
  • HS-25 - Drug Profile

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Lipid Modifying Drug
  • Mineral Supplement
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

The majority of AEs were gastrointestinal.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative